Phase separation of proSAAS into spheres results in core sequestration of TDP-43216-414 aggregates

Abstract

As neurons age, protein homeostasis becomes less efficient, resulting in misfolding and aggregation. Chaperone proteins perform vital functions in the maintenance of cellular proteostasis, and chaperone-based therapies that promote sequestration of toxic aggregates may prove useful in blocking the development of neurodegenerative disease. We previously demonstrated that proSAAS, a small secreted neuronal protein, exhibits potent chaperone activity against protein aggregation in vitro, and blocks the cytotoxic effects of amyloid and alpha synuclein oligomers in cell culture models. We now examine whether cytoplasmic expression of proSAAS results in interaction with protein aggregates in this cellular compartment. We used site-directed mutagenesis, confocal microscopy, in vitro aggregation assays, and functional assays to investigate the interaction of proSAAS with TDP-43 and other known aggregating proteins. We report that expression of proSAAS within the cytoplasm generates dense, membrane-less 2 m proSAAS spheres which progressively fuse to form larger spheres, suggesting liquid droplet-like properties. ProSAAS spheres selectively accumulate a C-terminally truncated fluorescently-tagged form of TDP-43216-414, initiating its cellular redistribution by sequestration within the sphere core; these TDP-43216-414 -containing spheres also exhibit dynamic fusion. Removal of either the predicted -helix (37-70) composed of hydrophobic and charged amino acids or the stretch of amino acids encompassing the conserved hydrophobic region and the positively charged furin site (163-189) inhibits the ability of proSAAS both to form spheres and to encapsulate TDP-43 aggregates. As a functional output, we demonstrate that proSAAS expression results in cytoprotection against full-length TDP-43 toxicity in yeast. In summary, the normally secreted neuronal chaperone proSAAS, when expressed in the cytoplasm unexpectedly phase-separates to form spherical liquid-like condensates that undergo dynamic fusion. We conclude that cyto-proSAAS acts as a functional holdase for cytoplasmic TDP-43216-414 molecules via this phase-separation property, representing a cytoprotectant whose unusual biochemical properties can potentially be exploited in the design of therapeutic molecules.